CT引导下经皮穿刺缓释顺铂瘤体内植入治疗非小细胞肺癌疗效

Treatment of non-small cell lung cancer with CT guided percutaneous cisplatin sustained release tumor implantation

目的研究分析CT引导下经皮穿刺缓释顺铂瘤体内植入治疗非小细胞肺癌疗效。方法选取本院2015年1月~2016年3月收治的80例非小细胞肺癌患者,随机分为对照组和实验组,每组患者各为40例。对照组进行诺维本加顺铂化疗治疗,实验组患者给予CT引导下经皮穿刺缓释顺铂瘤体内植入治疗。比较分析实验组与对照组患者的相关临床标准。结果经过治疗后,实验组患者的治疗无效例数为8例,有效例数为32例,治疗有效率为80.0%。对照组患者的治疗无效例数32例,有效例数为8例。可得,实验组患者的治疗有效率显著高于对照组,差异具有统计学差异（P〈0.05）。实验组患者一年生存率为77.5%显著高于对照组患者生存率60.0%,差异具有统计学差异（P〈0.05）。实验组患者发生不良反应的概率（37.5%）显著低于对照组（17.5%）,差异具有统计学差异（P〈0.05）。结论 CT引导下经皮穿刺缓释顺铂瘤体内植入治疗非小细胞肺癌治疗效果较好,在一定程度提高治疗有效率,安全性较高,具有进一步推广和应用的意义。

Objective To investigate and analyze the efficacy of CT guided percutaneous cisplatin cisplatin implantation in the treatment of nonsmall cell lung cancer. Methods 80 cases of non small cell lung cancer patients in our hospital from January 2015 to March 2016 were randomly divided into the control group and the experimental group,each group of 40 patients. The control group was treated with cisplatin and cisplatin,and the patients in the experimental group were treated with CT guided percutaneous cisplatin sustained-release implantation. The clinical standards of the experimental group and the control group were compared and analyzed. Results After treatment,the number of invalid cases in the experimental group was 8 cases,the effective number was 32 cases,the effective rate was 80%. The number of invalid cases in the control group was 32 cases,and the effective number was 8 cases. The effective rate of the patients in the experimental group was significantly higher than that in the control group（ P〈 0. 05）. The 1-year survival rate of the experimental group was 77. 5%,significantly higher than that of the control group,and the survival rate was 60%,with statistical difference（ P 〈0. 05）. The incidence of adverse reactions in the experimental group（ 37. 5%） was significantly lower than that in the control group（ 17. 5%）,with statistical difference（ P〈 0. 05）. Conclusion CT guided percutaneous treatment of percutaneous intratumoral implantation of slowrelease cisplatin in treatment of non-small cell lung cancer can improve the treatment efficiency in a certain degree,high security,with the further promotion and application significance.